These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

551 related items for PubMed ID: 19213078

  • 1. Giant lymphadenopathy infiltrated by gaucher cells mimicking lymphoma.
    Yağci B, Salor O, Yalçin B, Gürakan F, Güçer S, Büyükpamukçu M.
    Pediatr Blood Cancer; 2009 Jul; 52(7):870-1. PubMed ID: 19213078
    [Abstract] [Full Text] [Related]

  • 2. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
    Pastores GM.
    Curr Opin Investig Drugs; 2010 Apr; 11(4):472-8. PubMed ID: 20336596
    [Abstract] [Full Text] [Related]

  • 3. [Molecular diagnosis and gene therapy for Gaucher disease].
    Ohashi T.
    Nihon Rinsho; 1993 Sep; 51(9):2300-7. PubMed ID: 8411706
    [Abstract] [Full Text] [Related]

  • 4. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].
    Tóth J, Szücs FZ, Benkö K, Maródi L.
    Orv Hetil; 2003 Apr 20; 144(16):749-55. PubMed ID: 12778625
    [Abstract] [Full Text] [Related]

  • 5. [Gaucher's disease: pathogenesis, diagnosis and therapy].
    Pregun I, Tulassay Z.
    Orv Hetil; 2004 Sep 12; 145(37):1883-90. PubMed ID: 15493618
    [Abstract] [Full Text] [Related]

  • 6. [From gene to disease; Gaucher disease].
    Hollak CE, Boot RG, Poorthuis BJ, Aerts JM.
    Ned Tijdschr Geneeskd; 2005 Sep 24; 149(39):2163-6. PubMed ID: 16223076
    [Abstract] [Full Text] [Related]

  • 7. [Gaucher disease].
    Ohashi T.
    Nihon Rinsho; 1995 Dec 24; 53(12):2943-6. PubMed ID: 8577040
    [Abstract] [Full Text] [Related]

  • 8. Gaucher disease: progressive mesenteric and mediastinal lymphadenopathy despite enzyme therapy.
    Burrow TA, Cohen MB, Bokulic R, Deutsch G, Choudhary A, Falcone RA, Grabowski GA.
    J Pediatr; 2007 Feb 24; 150(2):202-6. PubMed ID: 17236903
    [Abstract] [Full Text] [Related]

  • 9. Gaucher Disease: Clinical, Biological and Therapeutic Aspects.
    Dandana A, Ben Khelifa S, Chahed H, Miled A, Ferchichi S.
    Pathobiology; 2016 Feb 24; 83(1):13-23. PubMed ID: 26588331
    [Abstract] [Full Text] [Related]

  • 10. Outcome of early-treated type III Gaucher disease patients.
    Lee NC, Chien YH, Wong SL, Sheen JM, Tsai FJ, Peng SF, Leung JH, Chao MC, Shun CT, Hwu WL.
    Blood Cells Mol Dis; 2014 Sep 24; 53(3):105-9. PubMed ID: 24984925
    [Abstract] [Full Text] [Related]

  • 11. [Gaucher disease: clinical, genetic and therapeutic aspects].
    Germain DP.
    Pathol Biol (Paris); 2004 Jul 24; 52(6):343-50. PubMed ID: 15261378
    [Abstract] [Full Text] [Related]

  • 12. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA).
    Hruska KS, LaMarca ME, Scott CR, Sidransky E.
    Hum Mutat; 2008 May 24; 29(5):567-83. PubMed ID: 18338393
    [Abstract] [Full Text] [Related]

  • 13. Phenotypic and genotypic heterogeneity in Gaucher disease type 1: a comparison between Brazil and the rest of the world.
    Sobreira E, Pires RF, Cizmarik M, Grabowski GA.
    Mol Genet Metab; 2007 Jan 24; 90(1):81-6. PubMed ID: 16996765
    [Abstract] [Full Text] [Related]

  • 14. Molecular analysis of Turkish Gaucher disease patients: identification of novel mutations in glucocerebrosidase (GBA) gene.
    Emre S, Gürakan F, Yüce A, Rolf A, Scott R, Ozen H.
    Eur J Med Genet; 2008 Jan 24; 51(4):315-21. PubMed ID: 18586596
    [Abstract] [Full Text] [Related]

  • 15. Gaucher disease: a lysosomal neurodegenerative disorder.
    Huang WJ, Zhang X, Chen WW.
    Eur Rev Med Pharmacol Sci; 2015 Apr 24; 19(7):1219-26. PubMed ID: 25912581
    [Abstract] [Full Text] [Related]

  • 16. Generation of a conditional knockout of murine glucocerebrosidase: utility for the study of Gaucher disease.
    Sinclair GB, Jevon G, Colobong KE, Randall DR, Choy FY, Clarke LA.
    Mol Genet Metab; 2007 Feb 24; 90(2):148-56. PubMed ID: 17079175
    [Abstract] [Full Text] [Related]

  • 17. Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients.
    Chang HH, Asano N, Ishii S, Ichikawa Y, Fan JQ.
    FEBS J; 2006 Sep 24; 273(17):4082-92. PubMed ID: 16934036
    [Abstract] [Full Text] [Related]

  • 18. Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene.
    Tybulewicz VL, Tremblay ML, LaMarca ME, Willemsen R, Stubblefield BK, Winfield S, Zablocka B, Sidransky E, Martin BM, Huang SP.
    Nature; 1992 Jun 04; 357(6377):407-10. PubMed ID: 1594045
    [Abstract] [Full Text] [Related]

  • 19. Molecular biology of glucocerebrosidase and the treatment of Gaucher disease.
    Barranger JA, Tomich J, Weiler S, Sakallah S, Sansieri C, Mifflin T, Bahnson A, Wei FS, Wei JF, Vallor M.
    Cytokines Mol Ther; 1995 Sep 04; 1(3):149-63. PubMed ID: 9384672
    [Abstract] [Full Text] [Related]

  • 20. [Gene therapy of Gaucher's and Fabry's diseases: current status and prospects].
    Fabrega S, Lehn P.
    J Soc Biol; 2002 Sep 04; 196(2):175-81. PubMed ID: 12360746
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.